Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.46 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096809 | 0.91 | RAB9A (0.51) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL3094799 | 0.89 | PTPN1 (0.58) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL3102653 | 0.88 | KDM4E (0.56) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL3105791 | 0.88 | MEN1 (0.56) | MEN1KMT2ACNR1 | |
| SCHEMBL3097312 | 0.88 | RAB9A (0.53) | NPC1SMN1; SMN2RAB9AKMT2AMAPT | |
| SCHEMBL3105673 | 0.87 | EPHX1 (0.54) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL3092820 | 0.87 | IDH1 (0.50) | NPC1SMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL3097120 | 0.87 | KIF11 (0.50) | NPC1RAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL13515935 | 0.86 | EPHX2 (0.48) | NPC1SMN1; SMN2RAB9AKMT2AMAPT | |
| SCHEMBL3755534 | 0.85 | POLB (0.56) | NPC1SMN1; SMN2RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | claimed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | claimed |
| EP-1912634-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Healthcare, LLC (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007016538-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2007-02-08 | — | — | WO | claimed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | NPC1 2959/4885SMN1; SMN2 4427/4885RAB9A 1741/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | NPC1 2959/4885SMN1; SMN2 4427/4885RAB9A 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.